ABO Blood Type Has No Impact on Survival in Patients with Epithelial Ovarian Cancer

Wang, Ling; Yang, Zhuo; Liu, Yi; Wang, Ya-Nan; Guo, Jing-Yi; Wu, Qi-Jun; Gong, Ting-Ting

doi:10.7150/jca.27734



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2018; 9(23):4334-4340. doi:10.7150/jca.27734 This issue Cite

Research Paper

ABO Blood Type Has No Impact on Survival in Patients with Epithelial Ovarian Cancer

Ling Wang¹, Zhuo Yang², Yi Liu², Ya-Nan Wang¹, Jing-Yi Guo¹, Qi-Jun Wu^3✉, Ting-Ting Gong^2✉

1. School of postgraduate, China Medical University, Shenyang, China.
2. Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.
3. Department of Clinical Epidemiology, Shengjing Hospital of China Medical University, Shenyang, China.

✉ Corresponding authors: Qi-Jun Wu, M.D., Ph.D. Department of Clinical Epidemiology, Shengjing Hospital of China Medical University, No.36, SanHao Street, Shenyang, Liaoning 110004, P. R. China. Phone: +86-24-96615-13648; Fax: +86-24-96615-13648; E-ma More

Citation:

Wang L, Yang Z, Liu Y, Wang YN, Guo JY, Wu QJ, Gong TT. ABO Blood Type Has No Impact on Survival in Patients with Epithelial Ovarian Cancer. J Cancer 2018; 9(23):4334-4340. doi:10.7150/jca.27734. https://www.jcancer.org/v09p4334.htm

Other styles

Abstract

Evidence for an association between ABO blood type and epithelial ovarian cancer (EOC) survival has so far been limited and conflictive. This study applied a retrospective cohort and included 627 EOC patients diagnosed at Shengjing Hospital of China Medical University between 2011 and 2015. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) between the ABO blood type and progression-free survival (PFS) and overall survival (OS) of EOC patients were assessed using multivariable Cox proportional regression models. The median follow-up duration was 2.97 years (inter-quartile range from 2.11 to 4.13 years). The recurrence and mortality rates were 41.5% (260/627) and 37.0% (232/627), respectively. Possessing a comorbidity, residual disease, ascites, and advanced FIGO stage (III/IV) were associated with worse PFS and OS of EOC patients. The distribution of blood types O, A, B, and AB among patients was 27.4%, 31.3%, 33.2%, and 8.1%, respectively. Compared with blood type O, none of the blood types (A, B, and AB) were significantly associated with PFS or OS. However, in the stratified analyses, we found borderline significant results for PFS with blood type AB (HR = 0.56, 95% CI = 0.31-1.01) compared with blood type O. No significant differences were observed for blood type A when compared with all non-A blood type cases. This study does not support an association between ABO blood type and EOC survival. Further prospective cohort studies are warranted to confirm our findings.

Keywords: blood type, epithelial ovarian cancer, retrospective cohort, survival

Citation styles

APA

Wang, L., Yang, Z., Liu, Y., Wang, Y.N., Guo, J.Y., Wu, Q.J., Gong, T.T. (2018). ABO Blood Type Has No Impact on Survival in Patients with Epithelial Ovarian Cancer. Journal of Cancer, 9(23), 4334-4340. https://doi.org/10.7150/jca.27734.

ACS

Wang, L.; Yang, Z.; Liu, Y.; Wang, Y.N.; Guo, J.Y.; Wu, Q.J.; Gong, T.T. ABO Blood Type Has No Impact on Survival in Patients with Epithelial Ovarian Cancer. J. Cancer 2018, 9 (23), 4334-4340. DOI: 10.7150/jca.27734.

NLM

CSE

Wang L, Yang Z, Liu Y, Wang YN, Guo JY, Wu QJ, Gong TT. 2018. ABO Blood Type Has No Impact on Survival in Patients with Epithelial Ovarian Cancer. J Cancer. 9(23):4334-4340.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.